Sarepta Therapeutics shares are trading lower after the company on Wednesday reported worse-than-expected Q2 sales results and issued FY25 net product revenue guidance below estimates.
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics shares are trading lower after the company reported worse-than-expected Q2 sales results and issued FY25 net product revenue guidance below estimates.
August 09, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sarepta Therapeutics shares are trading lower due to disappointing Q2 sales results and FY25 revenue guidance below estimates.
The company's worse-than-expected Q2 sales results and lower-than-expected FY25 revenue guidance are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100